1300 Participants Needed

TAK-279 for Psoriasis

Recruiting at 351 trial locations
TC
DP
Overseen ByDena Petersen
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

Will I have to stop taking my current medications?

The trial does not specify if you must stop taking your current medications, but it does mention that certain biologics and immune therapies should not have been used within specific time frames before starting the trial. It's best to discuss your current medications with the study team to see if they are allowed.

What data supports the effectiveness of the drug TAK-279 for treating psoriasis?

Research on similar drugs, like deucravacitinib, which also inhibit TYK2, shows they can be effective in treating moderate-to-severe plaque psoriasis. These drugs work by targeting specific pathways involved in the disease, potentially offering benefits with fewer side effects.12345

Is TAK-279 safe for humans?

Deucravacitinib, a similar TYK2 inhibitor, was found to be well tolerated and safe in clinical trials for psoriasis, with no serious infections or major side effects reported.16789

What makes the drug TAK-279 unique for treating psoriasis?

TAK-279 is a small molecule TYK2 inhibitor, which is a novel approach for treating psoriasis by specifically targeting the TYK2 enzyme involved in the immune response, potentially offering a more targeted treatment compared to traditional therapies.1011121314

Research Team

SD

Study Director

Principal Investigator

Takeda

Eligibility Criteria

This trial is for adults over 18 with chronic plaque psoriasis for at least 6 months, covering more than 10% of their body. They must be stable, without significant changes in their condition recently and be candidates for phototherapy or systemic therapy. Participants need to understand the study procedures and agree to follow them.

Inclusion Criteria

I have been diagnosed with chronic plaque psoriasis for at least 6 months.
Main
My psoriasis has been stable without major changes for at least 6 months.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

5 weeks

Treatment Part A

Participants receive TAK-279, oral tablet once daily for up to 52 weeks

52 weeks
Multiple visits (in-person)

Treatment Part B

Participants who complete Part A or parent studies receive TAK-279, oral tablet once daily for up to 156 weeks

156 weeks
Multiple visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • TAK-279
Trial OverviewThe trial tests TAK-279's safety and effectiveness in those with moderate-to-severe plaque psoriasis. It involves up to 217 weeks of treatment including a screening period, an initial treatment phase (Part A), an optional extended phase (Part B), and a follow-up.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Part A (De Novo Cohort) + Part B (Open Label Extension): TAK-279Experimental Treatment1 Intervention
Part A: Participants will receive TAK-279, oral tablet once daily (QD) for up to 52 weeks. Part B: Participants who completed the treatment period of parent studies (TAK-279-3001 \[NCT06088043\] or TAK-279-3002 \[NCT06108544\]) or who completed Part A will receive TAK-279, oral tablet QD for up to 156 weeks.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Takeda

Lead Sponsor

Trials
1,255
Recruited
4,219,000+
Dr. Naoyoshi Hirota profile image

Dr. Naoyoshi Hirota

Takeda

Chief Medical Officer since 2020

MD from University of Tokyo

Christophe Weber profile image

Christophe Weber

Takeda

Chief Executive Officer since 2015

PhD in Molecular Biology from Université de Montpellier

Findings from Research

In a phase IIa study involving 212 patients with moderate-to-severe plaque psoriasis, the oral TYK2/Jak1 inhibitor PF-06700841 showed significant improvements in psoriasis severity, with the 30 mg once daily dose achieving the greatest reduction in PASI score at week 12.
The treatment was generally well tolerated, with no cases of herpes zoster or major cardiac events reported, although some patients experienced adverse events leading to discontinuation of treatment.
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial.Forman, SB., Pariser, DM., Poulin, Y., et al.[2021]
Deucravacitinib, a new oral drug that selectively inhibits TYK2, showed significant efficacy in treating moderate-to-severe psoriasis, with over 50% of patients achieving PASI75 at week 16 in two phase 3 trials involving 1688 participants.
The drug was well tolerated with no serious infections or significant side effects reported, indicating a favorable safety profile that could make it a promising option for patients requiring systemic therapy.
Deucravacitinib in the treatment of psoriasis.Estevinho, T., Lé, AM., Torres, T.[2023]
Deucravacitinib, an oral TYK2 inhibitor, demonstrated significant efficacy in treating moderate to severe plaque psoriasis, with 65.1% of patients achieving a PASI 75 response at week 16 across 6 clinical trials involving 2248 subjects.
The safety profile of deucravacitinib is favorable, with mild adverse events like nasopharyngitis being common, and serious adverse events occurring in only 1.35% to 9.5% of patients, making it a potentially less burdensome treatment option compared to injectable therapies.
Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.Truong, TM., Pathak, GN., Singal, A., et al.[2023]

References

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial. [2021]
Deucravacitinib in the treatment of psoriasis. [2023]
Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis. [2023]
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis. [2023]
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. [2021]
The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells. [2019]
Deucravacitinib for the Treatment of Psoriatic Disease. [2022]
TYK2 in Immune Responses and Treatment of Psoriasis. [2022]
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. [2013]
12.United Statespubmed.ncbi.nlm.nih.gov
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. [2018]
13.United Statespubmed.ncbi.nlm.nih.gov
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. [2021]
14.United Statespubmed.ncbi.nlm.nih.gov
Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. [2021]